Table 5.
Risk of PTLDs by time since transplantation
| Variable | Time since transplantation, mo* |
|||||||
|---|---|---|---|---|---|---|---|---|
| Less than 3 mo |
3 to less than 6 mo |
6 to less than 12 mo |
More than 12 mo |
|||||
| No. PTLDs | RR (95% CI) | No. PTLDs | RR (95% CI) | No. PTLDs | RR (95% CI) | No. PTLDs | RR (95% CI) | |
| T-cell depletion methods | ||||||||
| Broad lymphocyte depletion† | 1 | 1.9 (0.1-9.3) | 0 | 0.0 (0.0-3.4) | 3 | 14.0 (2.8-59) | 2 | 3.4 (0.5-12) |
| Selective T-cell depletion† | 30 | 10.3 (5.1-21) | 24 | 12.3 (5.4-28) | 11 | 15.4 (4.2-58) | 3 | 4.2 (0.96-13) |
| ATG (preventative or acute GVHD treatment) | 23 | 5.4 (2.8-10) | 10 | 3.8 (1.6-8.2) | 4 | 3.2 (0.8-10) | 2 | 1.8 (0.3-6.9) |
| 2+ HLA antigen–mismatched related or unrelated donor | ||||||||
| No ATG, no selective T-cell depletion†‡ | 1 | 1.0 (0.1-5.1) | 1 | 0.8 (0.04-4.0) | 1 | 1.6 (0.1-9.4) | 1 | 0.7 (0.04-3.5) |
| ATG, selective T-cell depletion, or both† | 30 | 5.7 (2.8-12) | 17 | 2.8 (1.2-6.4) | 8 | 3.9 (1.2-14) | 0 | 0.0 (0.0-2.2) |
| Acute GVHD grade II-IV | 27 | 1.9 (1.1-3.5) | 19 | 1.8 (0.9-3.5) | 7 | 1.6 (0.5-4.2) | 9 | 1.2 (0.5-3.1) |
| Chronic GVHD moderate/severe or clinical extensive | 1 | 2.0 (0.1-9.4) | 8 | 2.3 (0.9-5.2) | 3 | 1.1 (0.2-3.8) | 10 | 3.0 (1.2-7.4) |
| Second transplantation§ | 0 | 0.0 (0.0-1.2) | 7 | 10.3 (3.9-24) | 3 | 7.0 (1.6-23) | 1 | 1.8 (0.1-9.3) |
| 50 y or older at transplantation | 3 | 2.7 (0.6-7.3) | 7 | 8.1 (3.2-18) | 2 | 3.9 (0.6-14) | 2 | 4.5 (0.7-16) |
| Total PTLD cases (person-years) | 48 | (5878) | 38 | (4560) | 19 | (7659) | 22 | (61 939) |
RR indicates relative risk; PTLD, posttransplantation lymphoproliferative disorder; CI, confidence interval; HLA-2Ag+/unrelated, 2+ HLA antigen–mismatched sibling/relative, or unrelated donor; ATG, antithymocyte globulin; and GVHD, graft-versus-host disease.
Latency is defined as time since first transplantation. Models are stratified by latency in 13 categories.
Broad lymphocyte depletion methods are alemtuzumab monoclonal antibody or elutriation/density gradient centrifugation; selective T-cell depletion methods include anti-T or anti-T+NK monoclonal antibodies, SRBC rosetting, or lectins with/without SRBC or anti-T monoclonal antibodies.
All PTLDs in this group were from HLA unrelated donors.
Second allogeneic transplantation among patients with a first allogeneic transplantation.